Financial reports
ARS
2023 FY
Annual report to shareholders
25 Apr 24
10-K
2023 FY
Annual report
26 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q3
Quarterly report
8 May 23
ARS
2022 FY
Annual report to shareholders
25 Apr 23
10-K
2022 FY
Annual report
6 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
Current reports
8-K
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
26 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K/A
Entry into a Material Definitive Agreement
22 Dec 23
8-K
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
21 Dec 23
8-K
Regulation FD Disclosure
20 Dec 23
8-K
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
13 Nov 23
8-K
Annexon Receives Prime Designation from the Ema for ANX007 for the Treatment of Geographic Atrophy
24 Oct 23
8-K
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal
11 Oct 23
8-K
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
7 Aug 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
5 Apr 24
S-3
Shelf registration
26 Mar 24
S-8
Registration of securities for employees
26 Mar 24
424B5
Prospectus supplement for primary offering
21 Dec 23
FWP
Free writing prospectus
20 Dec 23
S-8
Registration of securities for employees
6 Mar 23
424B3
Prospectus supplement
16 Nov 22
S-3
Shelf registration
4 Nov 22
S-8
Registration of securities for employees
8 Aug 22
D
$130.48M in equity / options / securities to be acquired, sold $130.48M, 12 investors
22 Jul 22
Proxies
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 23
DEF 14A
Definitive proxy
25 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 22
DEF 14A
Definitive proxy
27 Apr 22
DEFA14A
Additional proxy soliciting materials
22 Apr 21
DEF 14A
Definitive proxy
22 Apr 21
Other
EFFECT
Notice of effectiveness
2 Apr 24
EFFECT
Notice of effectiveness
17 Nov 22
CORRESP
Correspondence with SEC
14 Nov 22
UPLOAD
Letter from SEC
10 Nov 22
EFFECT
Notice of effectiveness
4 May 22
EFFECT
Notice of effectiveness
24 Jul 20
SEC STAFF
SEC staff action: Order
23 Jul 20
CERT
Certification of approval for exchange listing
22 Jul 20
CORRESP
Correspondence with SEC
21 Jul 20
CORRESP
Correspondence with SEC
21 Jul 20
Ownership
SC 13G
BB BIOTECH AG
22 Apr 24
4
William H. Carson
10 Apr 24
4
Douglas Love
21 Feb 24
4
Jamie Dananberg
21 Feb 24
4
DEAN RICHARD ARTIS
21 Feb 24
4
Jennifer Lew
21 Feb 24
4
Ted Yednock
21 Feb 24
4
Michael Overdorf
21 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
144
Notice of proposed sale of securities
20 Feb 24